Alto Neuroscience Company Leadership
| ANRO Stock | 16.16 0.35 2.21% |
Alto Neuroscience's insiders are aggressively buying. The analysis of insiders' sentiment of trading Alto Neuroscience stock suggests that virtually all insiders are extremely bullish at this time. Alto Neuroscience employs about 76 people. The company is managed by 11 executives with a total tenure of roughly 178 years, averaging almost 16.0 years of service per executive, having 6.91 employees per reported executive.
Insider Sentiment 100
Aggressively Buying
Selling | Buying |
Latest Trades
| 2024-07-09 | Adam Savitz | Acquired 12069 @ 12.6 | View | ||
| 2024-03-28 | Nicholas Conrad Smith | Acquired 6150 @ 16.36 | View | ||
| 2024-02-06 | Wave Global Lp Alpha | Acquired 600000 @ 16 | View |
Monitoring Alto Neuroscience's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alto Neuroscience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation. Alto Neuroscience Management Team Effectiveness
The company has return on total asset (ROA) of (0.2448) % which means that it has lost $0.2448 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4501) %, meaning that it created substantial loss on money invested by shareholders. Alto Neuroscience's management efficiency ratios could be used to measure how well Alto Neuroscience manages its routine affairs as well as how well it operates its assets and liabilities. As of the 4th of February 2026, Return On Tangible Assets is likely to drop to -0.33. In addition to that, Return On Capital Employed is likely to drop to -0.39. At this time, Alto Neuroscience's Total Assets are very stable compared to the past year. As of the 4th of February 2026, Non Current Assets Total is likely to grow to about 9.9 M, while Non Currrent Assets Other are likely to drop 3,420.As of the 4th of February 2026, Common Stock Shares Outstanding is likely to drop to about 20.5 MAlto Neuroscience holds a total of 31.07 Million outstanding shares. Over half of Alto Neuroscience's outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Some institutional investors establish a significant position in stocks such as Alto Neuroscience in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Alto Neuroscience, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Alto Neuroscience Workforce Comparison
Alto Neuroscience is rated below average in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 1,259. Alto Neuroscience holds roughly 76.0 in number of employees claiming about 6% of equities under Health Care industry.
Alto Neuroscience Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Alto Neuroscience insiders, such as employees or executives, is commonly permitted as long as it does not rely on Alto Neuroscience's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Alto Neuroscience insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Alto Neuroscience Notable Stakeholders
An Alto Neuroscience stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Alto Neuroscience often face trade-offs trying to please all of them. Alto Neuroscience's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Alto Neuroscience's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Wei Wu | CoFounder Officer | Profile | |
| B BCom | CoFounder CEO | Profile | |
| Amit MD | Chairman Founder | Profile | |
| Nicholas Smith | CFO Secretary | Profile | |
| Melissa Berman | Vice Accounting | Profile | |
| Michael MBA | Chief Officer | Profile | |
| Jason Hoffman | Vice Resources | Profile | |
| Erin JD | General Officer | Profile | |
| Adam MD | Chief Officer | Profile | |
| Fadi MD | Senior Innovation | Profile | |
| Jessica Powell | Chief Officer | Profile |
About Alto Neuroscience Management Performance
The success or failure of an entity such as Alto Neuroscience often depends on how effective the management is. Alto Neuroscience management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Alto management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Alto management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.31) | (0.33) | |
| Return On Capital Employed | (0.37) | (0.39) | |
| Return On Assets | (0.31) | (0.33) | |
| Return On Equity | (0.47) | (0.44) |
Alto Neuroscience Workforce Analysis
Traditionally, organizations such as Alto Neuroscience use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Alto Neuroscience within its industry.Alto Neuroscience Manpower Efficiency
Return on Alto Neuroscience Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 808.3K | |
| Net Loss Per Executive | 5.6M | |
| Working Capital Per Employee | 2.1M | |
| Working Capital Per Executive | 14.5M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alto Neuroscience. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation. To learn how to invest in Alto Stock, please use our How to Invest in Alto Neuroscience guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Will Pharmaceuticals sector continue expanding? Could Alto diversify its offerings? Factors like these will boost the valuation of Alto Neuroscience. If investors know Alto will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Alto Neuroscience data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Alto Neuroscience requires distinguishing between market price and book value, where the latter reflects Alto's accounting equity. The concept of intrinsic value - what Alto Neuroscience's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Alto Neuroscience's price substantially above or below its fundamental value.
Understanding that Alto Neuroscience's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Alto Neuroscience represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Alto Neuroscience's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.